Myxofibrosarcoma is a soft-tissue cancer that usually shows up as a painless, slow-growing mass on an arm or leg, and its deceptive resemblance to benign lumps is one of the biggest challenges patients and clinicians face. Formerly lumped under the “malignant fibrous histiocytoma” label, it is now recognized as a distinct fibroblastic tumor with a uniquely infiltrative growth pattern that drives local recurrence rates well above those of most other soft-tissue sarcomas. Understanding how it presents, how it is diagnosed, and what treatment options exist can make a real difference in outcomes.
How Myxofibrosarcoma Typically Presents
The most common symptom is a lump that grows slowly and does not hurt. Most people notice a mass somewhere on a limb, and because it does not cause pain, they may ignore it for weeks or months before seeking medical attention. The lower extremities are the most frequent site, followed by the upper extremities, with the trunk and neck far less common. Combined, the limbs account for roughly three-quarters of all cases.1MDPI Diagnostics. Giant Myxofibrosarcoma in the Lower Limb: An Overview of Diagnostic and Clinical Management Tumors can be superficial, sitting in the skin or just beneath it, or deep, extending into muscle and the tissue planes below the fascia.
Myxofibrosarcoma tends to affect older adults. The median age at diagnosis in large series hovers around 70 years.2Oncology Research and Treatment. Grading in Myxofibrosarcoma of the Extremities Can Predict Survival and Local Control That does not mean younger people are immune, but a painless soft-tissue mass in someone over 60 should raise suspicion. Size varies enormously at the time of discovery, partly because the tumor’s slow, painless growth lets it go unnoticed for a long time.
Why It Gets Mistaken for Something Harmless
One of the most frustrating features of myxofibrosarcoma is how easily it fools clinicians. When the tumor sits in the superficial soft tissue, it can look and feel like a cyst, ganglion, or benign fatty lump. Its low-grade forms are predominantly myxoid, meaning they are soft and jelly-like, and under a microscope they can closely resemble benign myxoid tumors of the skin.3PubMed. Myxofibrosarcoma presenting in the skin: clinicopathological features and differential diagnosis with cutaneous myxoid neoplasms That resemblance leads to real diagnostic errors.
A study of subcutaneous myxofibrosarcoma cases referred to a specialist center found that more than half had been misdiagnosed before referral. Seven patients experienced referral delays of over six months, and several underwent unplanned biopsies or unplanned excisions before anyone suspected cancer. Previous diagnoses included myxoma, fasciitis, ganglion, cyst, and pyogenic granuloma.4Japanese Journal of Clinical Oncology. Diagnostic errors in subcutaneous myxofibrosarcoma: a retrospective case series before referral to specialist in bone and soft tissue tumors An unplanned excision is especially problematic because removing a sarcoma without proper margins can scatter tumor cells and make definitive surgery harder.
The practical takeaway is that any soft-tissue lump that keeps growing, especially in an older adult, deserves imaging and specialist evaluation rather than a quick office excision. The default assumption should not be that it is benign.
Imaging and the Tail Sign
MRI is the imaging workhorse for myxofibrosarcoma. Because the tumor has a rich myxoid matrix, it lights up brightly on fluid-sensitive MRI sequences, sometimes looking almost like a fluid collection. Two imaging features stand out. The first is a “water-like” signal intensity that reflects the gelatinous makeup of the tumor. The second is the so-called “tail sign,” a finger-like extension of tumor tissue that stretches away from the main mass along fascial planes.
The tail sign is not just a curiosity. In a study comparing myxofibrosarcoma cases with other soft-tissue tumors, the tail sign had a sensitivity of roughly 64 to 77 percent and a specificity of about 79 to 90 percent for distinguishing myxofibrosarcoma from other masses.5PubMed Central. Myxofibrosarcoma: prevalence and diagnostic value of the “tail sign” on magnetic resonance imaging It is associated with myxofibrosarcoma strongly enough to help radiologists flag the diagnosis before biopsy results come in. And the tail sign carries prognostic weight: it is linked to a higher risk of local recurrence after surgery and to a higher risk of distant spread at the time of diagnosis.6PubMed. Magnetic resonance imaging of soft tissue sarcoma: features related to prognosis
Those infiltrative tails are a visual reminder of why myxofibrosarcoma is so hard to cut out cleanly. The tumor does not respect anatomical boundaries. It extends along blood vessels and fascial layers in ways that can be invisible to the naked eye during surgery, even when they show up faintly on MRI.
Biopsy and What the Pathologist Looks For
Imaging raises suspicion, but biopsy confirms the diagnosis. Image-guided core needle biopsy is the standard approach for soft-tissue masses suspected of being sarcomas. For distinguishing benign from malignant lesions, core needle biopsy has been shown to be highly accurate, and it performs well at grading tumors too, although grade determination is somewhat less reliable than the benign-versus-malignant call.7Current Problems in Diagnostic Radiology. Image-guided core needle biopsy for soft tissue sarcomas: Diagnostic accuracy in determining grade and malignant potential
Under the microscope, myxofibrosarcoma has a recognizable look: a nodular growth pattern, a myxoid background studded with elongated, curving blood vessels, and spindle-shaped or star-shaped tumor cells with dark, irregular nuclei.8PubMed. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant The pathologist also assigns a grade, usually on a three-tier scale from grade 1 (low) to grade 3 (high), based on how abnormal the cells look, how many are dividing, and how much dead tissue is present in the tumor.
Grading matters a great deal. In a series of 229 patients with limb myxofibrosarcoma, roughly three-quarters had grade 3 tumors. Five-year disease-specific survival was 100 percent for grade 1, about 92 percent for grade 2, and around 73 percent for grade 3. Grade 1 tumors also had the lowest local recurrence risk, with none recurring within five years.2Oncology Research and Treatment. Grading in Myxofibrosarcoma of the Extremities Can Predict Survival and Local Control The catch is that low-grade tumors make up only a small fraction of cases, so most patients face a more aggressive version of the disease.
Surgery and the Margin Problem
Surgery is the primary treatment. The goal is to remove the tumor with a rim of normal tissue around it, what surgeons call a negative or “clear” margin. For many solid tumors, achieving a clear margin is relatively straightforward. Myxofibrosarcoma makes it unusually difficult. The infiltrative growth pattern, those tails extending along fascial planes and blood vessels, means that microscopic disease can extend well beyond what the surgeon sees and what even MRI reveals.
Research has shown that even when surgeons achieve a clear margin, it may not be enough to prevent recurrence if that margin is narrow. One study found that a surgical margin of 2 millimeters was not sufficient to significantly reduce recurrence risk, suggesting wider margins may be needed.9Scientific Reports. Clear surgical margins as a prognostic indicator for disease recurrence, with no impact on survival rates in patients with myxofibrosarcoma At the same time, taking wider margins on a limb is not always possible without sacrificing major nerves, blood vessels, or functional muscle. This tension between oncologic adequacy and limb preservation is the central surgical challenge.
When a margin comes back positive (meaning tumor cells are found at the edge of the resected tissue), the risk of local recurrence jumps dramatically. In one retrospective review, positive margins at primary resection increased the odds of local recurrence more than eightfold.10PubMed. Tumor-associated mortality and prognostic factors in myxofibrosarcoma – A retrospective review of 109 patients That finding underscores why the initial operation matters so much: getting it right the first time gives the patient the best shot at avoiding re-excision or further treatment.
The Role of Radiation Therapy
Because clean margins are so hard to achieve, radiation is commonly added to surgery. Radiation can be delivered before surgery (neoadjuvant) or after (adjuvant), and the timing may matter more than whether radiation is used at all. In one institutional series, local recurrence was much more common in patients who received radiation after surgery compared with those who received it before, though the numbers were small and the difference did not reach statistical significance.11PubMed Central. Is Perioperative Radiotherapy Effective in Preventing Local Recurrence in Myxofibrosarcoma?
The rationale for giving radiation before surgery is that it may shrink the tumor and sterilize the infiltrative edges, making a clean resection more achievable. Preoperative radiation also treats the tumor while its blood supply is intact, potentially making the radiation more effective at killing cancer cells. Postoperative radiation treats the surgical bed after it has been disrupted and the remaining tissue may be less well oxygenated.
A broader systematic review found that radiation, regardless of timing, did not significantly affect local recurrence rates or overall survival in myxofibrosarcoma.12PubMed. The effect of radiation or chemotherapy on the local recurrence, overall survival, and distant metastasis in patients with myxofibrosarcoma: A systematic review That does not mean radiation is useless, but it does highlight that the evidence base is thinner than many patients might assume. Most sarcoma centers still include radiation in the treatment plan for intermediate- and high-grade tumors, especially when margins are close, but there is real debate about how much it helps for this particular subtype.
Chemotherapy and Systemic Options
Chemotherapy enters the picture mainly for advanced or metastatic disease. The standard first-line regimen for soft-tissue sarcomas has long been anthracycline-based, sometimes combined with ifosfamide. For myxofibrosarcoma specifically, data on chemotherapy effectiveness are limited. A series of 13 patients with advanced disease treated with anthracycline plus ifosfamide showed modest results: four partial responses, three cases of stable disease, and six cases where the cancer continued to grow, with a median time before progression of four months.13PubMed Central. Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma
The same systematic review that examined radiation also looked at chemotherapy and found that it was significantly associated with lower rates of distant metastasis, although it did not improve overall survival or local recurrence rates.12PubMed. The effect of radiation or chemotherapy on the local recurrence, overall survival, and distant metastasis in patients with myxofibrosarcoma: A systematic review This is a nuanced finding. Chemotherapy may help control distant spread, which is the leading cause of death in high-grade sarcomas, but the survival benefit has not been clearly demonstrated in this subtype. Other regimens, such as gemcitabine combined with docetaxel, are also used in practice for advanced disease.14PubMed Central. Management of Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma
Recurrence and What Drives It
Myxofibrosarcoma has a reported local recurrence rate of roughly 17 to 54 percent, which is high compared to soft-tissue sarcomas generally.15Sarcoma. High Recurrence Rate of Myxofibrosarcoma: The Effect of Radiotherapy Is Not Clear That wide range reflects differences in surgical technique, margin status, and whether radiation was used. What makes the recurrence story unusual is that it does not track neatly with tumor grade. In many cancers, higher grade means higher recurrence. For myxofibrosarcoma, the infiltrative growth pattern itself appears to be the main driver of local recurrence, regardless of whether the tumor is low-grade or high-grade.
Grade does predict something else: distant metastasis and death. High-grade tumors are far more likely to spread to the lungs or other distant sites, and grade has been identified as an independent risk factor for decreased disease-specific survival and distant-metastasis-free survival.10PubMed. Tumor-associated mortality and prognostic factors in myxofibrosarcoma – A retrospective review of 109 patients So a patient with a low-grade tumor may face repeated local recurrences that require additional surgeries but is unlikely to die of the disease. A patient with a high-grade tumor faces the double threat of local recurrence and the possibility of distant spread.
Prognosis and the Factors That Matter Most
Survival for myxofibrosarcoma depends on a handful of well-established factors. A large epidemiological study found that age 65 or older, male sex, tumor size greater than 5 centimeters, deep tumor location, high histological grade, the presence of distant metastases, not having surgery, and positive surgical margins all independently predicted worse overall survival. Patients 65 and older had nearly three times the risk of death compared with younger patients.16PubMed Central. Overall Survival of Patients with Myxofibrosarcomas: An Epidemiological Study
For a patient with a small, superficial, low-grade tumor that is completely excised, the outlook is generally favorable. For someone with a large, deep, high-grade tumor with close or positive margins, the prognosis is more guarded, and the treatment conversation shifts toward discussing radiation, possibly chemotherapy, and certainly close surveillance. Recurrence can happen late, sometimes years after the initial surgery, so long-term follow-up with periodic imaging is standard practice.
Molecular Landscape and Emerging Therapies
Myxofibrosarcoma does not have a single defining genetic mutation the way some cancers do, but large-scale sequencing studies have identified a pattern. The most commonly altered gene is TP53, mutated in about 46 percent of cases. Other frequently affected genes include RB1, CDKN2A, CDKN2B, NF1, and NTRK1. In total, mutations affecting potential therapeutic targets were found in roughly 39 percent of tumors studied.17Nature Communications. Integrated genetic and epigenetic analysis of myxofibrosarcoma The central molecular theme is disruption of the p53 pathway and cell-cycle control mechanisms.18PubMed Central. Integrated genetic and epigenetic analysis of myxofibrosarcoma
From a treatment standpoint, the presence of targetable mutations in a meaningful fraction of tumors opens doors for precision approaches, though most remain investigational. NTRK fusions, for example, can be targeted by drugs already approved for other cancers. NF1 loss may sensitize tumors to certain signaling-pathway inhibitors. These are still early days for targeted therapy in myxofibrosarcoma, and no targeted drug has become a standard recommendation yet.
Immunotherapy is another area of active interest. About a third of high-grade myxofibrosarcomas express PD-L1, a protein that tumors use to evade the immune system, and PD-L1 positivity in these tumors was associated with higher levels of immune cells within the tumor.19PubMed. Molecular and clinicopathological analysis revealed an immuno-checkpoint inhibitor as a potential therapeutic target in a subset of high-grade myxofibrosarcoma Immune checkpoint inhibitors, the same drugs that have transformed treatment for melanoma and lung cancer, may benefit a subset of myxofibrosarcoma patients. Clinical trials are ongoing, and while the results are not yet mature, the biological rationale is there for roughly one in three high-grade cases.
Life After Surgery for Limb Sarcomas
Because myxofibrosarcoma so often occurs on the limbs, functional recovery after surgery is a major concern. Limb-salvage surgery is the goal whenever possible, but excising a tumor with adequate margins can require removing significant muscle, skin, or other tissue. Reconstructive surgery using tissue flaps is frequently needed, especially for tumors on the foot or lower leg.20Foot & Ankle Surgery: Techniques, Reports & Cases. Limb salvage surgery without radiation therapy for soft tissue sarcomas of the foot
A study examining functional outcomes and quality of life after lower-extremity sarcoma surgery found that several factors predicted worse function: older age, higher body mass index, having needed reconstructive surgery, and having received radiation therapy. Age and body weight also predicted lower overall quality of life.21PubMed Central. Soft Tissue Sarcoma of Lower Extremity: Functional Outcome and Quality of Life These findings are worth knowing because they highlight that the treatment burden can be considerable, and recovery planning should start before the operation. Physical therapy, wound care, and sometimes psychological support are all part of the picture.
Patients with superficial, small tumors that do not require extensive reconstruction tend to return to normal activity relatively quickly. Those who need large resections, flap coverage, and postoperative radiation face a longer and more difficult road. Given that myxofibrosarcoma primarily strikes older adults, age-related frailty and other health conditions can further complicate recovery. Discussions about treatment goals should weigh the cancer risk against the functional cost, especially for low-grade tumors where the threat to life is minimal but the impact of aggressive surgery on daily function may not be.
The Reclassification That Changed the Name
If you encounter older medical records or literature that mentions “myxoid malignant fibrous histiocytoma,” it is the same disease. For decades, myxofibrosarcoma was classified under the broad and somewhat vague umbrella of malignant fibrous histiocytoma, a category that lumped together several different tumor types based on their microscopic resemblance to fibrous and histiocytic cells. As molecular and pathological understanding improved, researchers realized these tumors were not all the same disease. The 2020 World Health Organization classification of soft-tissue tumors formally recognizes myxofibrosarcoma as a purely fibroblastic tumor, distinct from its former parent category.22PubMed Central. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives This reclassification matters clinically because treatment decisions and prognosis are more accurately calibrated when the specific tumor type is correctly identified rather than being grouped into a catch-all bin.